Ipertensione polmonare in corso di malattie parenchimali polmonari: Quali prospettive terapeutiche?

Translated title of the contribution: Pulmonary hypertension secondary to parenchimal lung diseases: Treatment perspectives

Research output: Contribution to journalReview article

Abstract

Pulmonary hypertension secondary to lung diseases, as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), is a relatively common condition with a bad prognosis. During the last World Congress in Nizza, detailed instructions about pulmonary hypertension secondary to lung diseases were provided. Long-term oxygen therapy is not able to normalize pulmonary artery pressure (PAP) values or to counteract vascular remodeling; the use of specific drug for pulmonary hypertension secondary to COPD or IPF, especially in severe forms, has often been suggested, but full indications have not yet been supplied.

Translated title of the contributionPulmonary hypertension secondary to parenchimal lung diseases: Treatment perspectives
Original languageItalian
Pages (from-to)131-136
Number of pages6
JournalRassegna di Patologia dell'Apparato Respiratorio
Volume31
Issue number3
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Pulmonary hypertension secondary to parenchimal lung diseases: Treatment perspectives'. Together they form a unique fingerprint.

  • Cite this